Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $26.14 million. The enterprise value is $2.89 million.

Market Cap	26.14M
Enterprise Value	2.89M

Important Dates

The last earnings date was Tuesday, March 3, 2026, before market open.

Earnings Date	Mar 3, 2026
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 3.21 million shares outstanding. The number of shares has increased by 3.06% in one year.

Current Share Class	3.21M
Shares Outstanding	3.21M
Shares Change (YoY)	+3.06%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	0.50%
Owned by Institutions (%)	42.48%
Float	2.89M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.33
P/TBV Ratio	1.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.07, with a Debt / Equity ratio of 1.28.

Current Ratio	2.07
Quick Ratio	2.01
Debt / Equity	1.28
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -113.78% and return on invested capital (ROIC) is -41.65%.

Return on Equity (ROE)	-113.78%
Return on Assets (ROA)	-32.75%
Return on Invested Capital (ROIC)	-41.65%
Return on Capital Employed (ROCE)	-110.08%
Weighted Average Cost of Capital (WACC)	7.42%
Revenue Per Employee	n/a
Profits Per Employee	-$1.90M
Employee Count	24
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	1.86
52-Week Price Change	n/a
50-Day Moving Average	9.09
200-Day Moving Average	8.55
Relative Strength Index (RSI)	49.74
Average Volume (20 Days)	44,540

Short Selling Information

The latest short interest is 98,369, so 3.07% of the outstanding shares have been sold short.

Short Interest	98,369
Short Previous Month	91,327
Short % of Shares Out	3.07%
Short % of Float	3.41%
Short Ratio (days to cover)	2.71

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-43.15M
Pretax Income	-45.52M
Net Income	-45.52M
EBITDA	-42.42M
EBIT	-43.15M
Earnings Per Share (EPS)	-$14.35

Full Income Statement

Balance Sheet

The company has $46.30 million in cash and $24.01 million in debt, with a net cash position of $22.29 million or $6.95 per share.

Cash & Cash Equivalents	46.30M
Total Debt	24.01M
Net Cash	22.29M
Net Cash Per Share	$6.95
Equity (Book Value)	18.76M
Book Value Per Share	5.89
Working Capital	24.68M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-31.51M
Capital Expenditures	n/a
Depreciation & Amortization	728,000
Net Borrowing	n/a
Free Cash Flow	-31.51M
FCF Per Share	-$9.82

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.06%
Shareholder Yield	-3.06%
Earnings Yield	-180.78%
FCF Yield	-125.13%

Analyst Forecast

The average price target for Passage Bio is $24.80, which is 204.29% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$24.80
Price Target Difference	204.29%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date	Jul 14, 2025
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	1